Otsuka and Lundbeck’s schizophrenia treatment gains EC approval

Lundbeck, which has offices in Bothell, Washington, announced the European Commission approved Otsuka Pharmaceutical Europe and H Lundbeck’s Abilify Maintena 720mg/960mg (aripiprazole) for schizophrenia treatment.

The treatment is the first introduction of a once-every-two-month long-acting injectable in the European Union for this indication.

According to Dr. Johan Luthman, Lundbeck research and development executive vice president and head, “Specifically designed for adult patients with schizophrenia who have been stabilised with aripiprazole, this treatment aims to increase patient adherence and convenience, contributing to the careful and comprehensive management of this chronic condition.”

READ THE STORY at Pharmaceutical Technology »